media – Page 678 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

FDA Clears First Device to Help Curb Opioid Cravings

The US Food and Drug Administration (FDA) has approved a device designed to reduce the symptoms of opioid withdrawal.
- Source: medscape
- 636
- November 16, 2017
cranial nerves FDA New Approvals opioid stimulator
Medical first-Doctors attempt to gene-edit a living patient’s DNA

A man may soon be forever free of the previously incurable disease he was born with 44 years ago. On Monday, in a medical first, Brian Madeux received an experimental in-body gene-editing treatment intended to cure him of Mucopolysaccharidoses II, known as MPS II or Hunter syndrome, a rare disorder that causes progressive damage to the body's cells.
- Source: flipboard
- 483
- November 16, 2017
enzyme Hunter syndrome Market Views mucopolysaccharides
New dye gives scientists a clearer insight into the brain

Keele University researchers have designed a new dye that can be used to observe the electrical activity of neurons in the brain and could lead to finding a new and more efficient way of treating neurological diseases, as presented at the Society for Neuroscience annual conference in Washington, D.C. this week.
- Source: sciencedaily
- 488
- November 16, 2017
neurological Researches
Boehringer bags first biosimilar approval in the EU

Boehringer Ingelheim has won its first biosimilar approval in Europe with authorisation of Cyltezo for a range of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
- Source: Pharmatimes
- 661
- November 16, 2017
arthritis biosimilar chronic Cyltezo New Approvals
Loxo Oncology Lands $1.55B Cancer Tie-Up With Bayer

Loxo Oncology struck a deal with Germany-based Bayer AG to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55 billion for the Connecticut-based company.
- Source: Biospace
- 962
- November 16, 2017
cancer larotrectinib Market Views therapy TRK
Cholesterol Crystals Are Sure Sign A Heart Attack May Loom

A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.
- Source: scienmag
- 617
- November 15, 2017
atherosclerosis cholesterol coronary arteries Researches
Eight cases of tuberculosis confirmed at Hong Kong secondary school

The Hong Kong health authorities have confirmed that eight people from a secondary school in Sha Tin were infected with tuberculosis.
- Source: scmp
- 574
- November 15, 2017
Market Views tuberculosis
AstraZeneca-FASENRA Gets US FDA Approval For Severe Eosinophilic Asthma

AstraZeneca and its global biologics research and development arm, MedImmune, said Tuesay that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. FASENRA is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.
- Source: businessinsider
- 620
- November 15, 2017
asthma eosinophilic Market Views New Approvals
Perflow Medical Announces Issuance of Patent for The Stream™ Dynamic Neuro-Thrombectomy Net to Improve Thrombus Removal Post-Stroke

Perflow Medical, an Israeli-based medtech company focused on next-generation neurointerventional devices,announced the issuance of U.S. Patent No. 9510855, by the U.S. Patent and Trademark Office (USPTO), for the Stream™ Dynamic Neuro-Thrombectomy Net. This is the first device to provide full dynamic wall apposition during the treatment of acute ischemic stroke.
- Source: Prnewswire
- 584
- November 15, 2017
ischemic stroke neurointerventional New Approvals
US regulators approve first digital pill to track patients

US regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns. The digital pill approved Monday combines two existing products: the former blockbuster psychiatric medication Abilify—long used to treat schizophrenia and bipolar disorder—with a sensor tracking system first approved in 2012.
- Source: medicalxpress
- 562
- November 15, 2017
bipolar disorder blockbuster New Approvals psychiatric schizophrenia

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.